October marks the beginning of both the RSV viral season and RSV awareness month. The National Coalition for Infant Health is taking the opportunity to
Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which
Preliminary data from the Institute for Patient Access suggest what opponents of non-medical switching have long suspected: having medications switched for financial reasons could be
Since the advent of biosimilars, experts and pundits have debated how reduced biosimilar prices will be and just much savings the follow-on drugs will offer.
New data show that street drugs, not prescription opioids, directly caused 85 percent of opioid overdose deaths in Massachusetts during 2013 and 2014. The state
What if discussing clinical trials opportunities were a standard part of patient care? This question spurred discussion among members of a diverse panel at a